California State Teachers Retirement System lifted its position in Glaukos Corporation (NYSE:GKOS) by 54.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,752 shares of the medical instruments supplier’s stock after buying an additional 17,800 shares during the quarter. California State Teachers Retirement System owned about 0.15% of Glaukos Corporation worth $2,105,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of GKOS. Prudential Financial Inc. acquired a new stake in shares of Glaukos Corporation in the first quarter worth $204,000. FMR LLC acquired a new stake in shares of Glaukos Corporation in the first quarter worth $7,323,000. Teachers Advisors LLC lifted its stake in shares of Glaukos Corporation by 6.2% in the first quarter. Teachers Advisors LLC now owns 29,512 shares of the medical instruments supplier’s stock worth $1,514,000 after buying an additional 1,723 shares during the last quarter. California Public Employees Retirement System acquired a new stake in shares of Glaukos Corporation in the first quarter worth $390,000. Finally, Vanguard Group Inc. raised its stake in Glaukos Corporation by 17.6% during the 1st quarter. Vanguard Group Inc. now owns 1,612,838 shares of the medical instruments supplier’s stock valued at $82,739,000 after purchasing an additional 241,772 shares during the last quarter.
Shares of Glaukos Corporation (NYSE GKOS) opened at $28.65 on Wednesday. The stock has a market cap of $1,036.96, a price-to-earnings ratio of 250.00 and a beta of 1.25. Glaukos Corporation has a fifty-two week low of $28.63 and a fifty-two week high of $52.49.
Glaukos Corporation (NYSE:GKOS) last announced its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.06. The firm had revenue of $40.41 million for the quarter, compared to analyst estimates of $38.69 million. Glaukos Corporation had a negative net margin of 0.64% and a positive return on equity of 3.50%. The business’s revenue for the quarter was up 36.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.03 EPS. equities analysts anticipate that Glaukos Corporation will post -0.02 earnings per share for the current year.
In other Glaukos Corporation news, Director Orbimed Advisors Llc sold 580,200 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $38.73, for a total value of $22,471,146.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Thomas William Burns sold 1,212 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $41.25, for a total transaction of $49,995.00. The disclosure for this sale can be found here. Insiders sold a total of 980,200 shares of company stock worth $37,900,263 in the last three months. Insiders own 16.40% of the company’s stock.
GKOS has been the subject of several research analyst reports. Stifel Nicolaus reiterated a “buy” rating on shares of Glaukos Corporation in a research note on Thursday, September 14th. Zacks Investment Research cut shares of Glaukos Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. BidaskClub upgraded shares of Glaukos Corporation from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Piper Jaffray Companies reiterated a “buy” rating and set a $38.00 target price on shares of Glaukos Corporation in a research note on Friday, September 15th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $54.00 target price on shares of Glaukos Corporation in a research note on Friday, September 1st. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $46.86.
TRADEMARK VIOLATION WARNING: “California State Teachers Retirement System Has $2.11 Million Stake in Glaukos Corporation (GKOS)” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/11/15/california-state-teachers-retirement-system-has-2-11-million-stake-in-glaukos-corporation-gkos.html.
Glaukos Corporation Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.